

GASTROENTEROLOGY AND DIGESTIVE DISORDERS

August 06-07, 2018 Abu Dhabi, UAE

Direct acting antivirals and hepatocellular carcinoma correlations

M A Ezzel Arab
NHTMRI, Egypt

Hepatocellular Carcinoma (HCC) is increasing worldwide and particularly in Egypt, where the prevalence of hepatitis C viral (HCV) infection, a well-established HCC risk factor, is the highest in the world. Direct-acting antivirals (DAAs) have completely changed the panorama of hepatitis C due to their high efficacy and optimal safety profile. The impact of DAA-based treatment on the incidence of HCC in patients with cirrhosis and particularly on the incidence of HCC recurrence after successful curative treatment has emerged as a controversial issue with potential clinical implications. As Egypt achieved the highest number (>1.5 million) of treated patients by DAAs globally up till now, it is so important to evaluate its situation in this issue. The talk will highlight on the following items: Discrepancy regarding the occurrence and recurrence of HCC, highlight on some Egyptian studies and possible factors contributing to increased HCC incidence/recurrence by DAAs.

Biography

M A Ezzel Arab is a Professor of Internal Medicine and Hepatology. He is the Founder of Intervention and Hepatoma Unit at the National Hepatology and Tropical Medicine Research Institute (NHTMRI) since 2007. He is a member of the steering committee which put the Egyptian guidelines for HCC (2011) which was sponsored by the Egyptian Society of Liver Cancer (ESLC).

ezz2006arab@hotmail.com

Notes: